Placebo design, reporting compliance, and methodological problems in randomized, placebo-controlled trials of Chinese herbal medicine: A cross-sectional study

This publication has 38 references indexed in Scilit:

• Improving the Reporting on Health Equity in Observational Research (STROBE-Equity)
  JAMA Network Open, 2025
• AI driven network pharmacology: Multi-scale mechanisms of traditional Chinese medicine from molecular to patient analysis
  Computational and Structural Biotechnology Journal, 2025
• Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial
  European Journal of Cancer, 2024
• Oral Liushen pill for patients with COVID‐19: A prospective randomized controlled trial
  Pulmonary Circulation, 2023
• 391P Traditional Chinese medicine jianpi-bushen formula enhancing completion rate of adjuvant chemotherapy for stage II and III colon cancer: A multi-center randomized placebo-controlled clinical trial in China
  Annals of Oncology, 2022
• Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine
  Journal of Integrative Medicine, 2022
• Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines)
  The Lancet, 2020
• Efficacy of lianhuaqingwen granules in the management of chronic rhinosinusitis without nasal polyps
  American Journal of Otolaryngology, 2020
• Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration
  Journal of Clinical Epidemiology, 2006
• THE POWERFUL PLACEBO
  JAMA, 1955